-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target

Benzinga·10/12/2026 11:33:07
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.